310 related articles for article (PubMed ID: 12435858)
1. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.
Rait AS; Pirollo KF; Xiang L; Ulick D; Chang EH
Mol Med; 2002 Aug; 8(8):475-86. PubMed ID: 12435858
[TBL] [Abstract][Full Text] [Related]
2. HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents.
Rait AS; Pirollo KF; Ulick D; Cullen K; Chang EH
Ann N Y Acad Sci; 2003 Dec; 1002():78-89. PubMed ID: 14751825
[TBL] [Abstract][Full Text] [Related]
3. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
Xu L; Tang WH; Huang CC; Alexander W; Xiang LM; Pirollo KF; Rait A; Chang EH
Mol Med; 2001 Oct; 7(10):723-34. PubMed ID: 11713371
[TBL] [Abstract][Full Text] [Related]
4. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
6. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.
Waterhouse DN; Gelmon KA; Masin D; Bally MB
J Exp Ther Oncol; 2003; 3(5):261-71. PubMed ID: 14696623
[TBL] [Abstract][Full Text] [Related]
7. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment.
Jhaveri MS; Rait AS; Chung KN; Trepel JB; Chang EH
Mol Cancer Ther; 2004 Dec; 3(12):1505-12. PubMed ID: 15634643
[TBL] [Abstract][Full Text] [Related]
11. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
Witters LM; Santala SM; Engle L; Chinchilli V; Lipton A
Am J Clin Oncol; 2003 Feb; 26(1):50-4. PubMed ID: 12576925
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
13. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
14. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
15. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
18. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
Hu Q; Bally MB; Madden TD
Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
[TBL] [Abstract][Full Text] [Related]
19. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.
Li S; Deshmukh HM; Huang L
Pharm Res; 1998 Oct; 15(10):1540-5. PubMed ID: 9794495
[TBL] [Abstract][Full Text] [Related]
20. [Optimal effects of liposome on antisense oligodeoxynucleotides uptake by mouse breast cancer TM40D cells and the effects of antisense oligodeoxynucleotides targeting c-erbB-2 on cell proliferation and apoptosis].
Liu XA; Fan P; Wu ZY
Zhonghua Wai Ke Za Zhi; 2004 Jul; 42(13):802-5. PubMed ID: 15363300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
